DYADIC INTERNATIONAL INC (DYAI)

Company Profile

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida. The company went IPO on 2004-11-05. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for industrial applications. This technology is based on the Thermothelomyces heterothallica fungus, namely C1. The C1-cell protein production platform is a robust and versatile thermophilic filamentous fungal expression system for the development and production of biologic products, including enzymes and other proteins for human and animal health. The firm also developed the Dapibus thermophilic filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of proteins, metabolites and other biologic products for use in non-pharmaceutical applications, such as food, nutrition and wellness.

Company Info

DYADIC INTERNATIONAL INC

1044 North U.S. Highway One, Suite 201

Jupiter FLORIDA 33477

P: 15617438333

CEO: Mark A. Emalfarb

Employees: 7

Website: https://dyadic.com/